Literature DB >> 17470854

Targeted therapy trials: approval strategies, target validation, or helping patients?

Paulo M Hoff, Lee M Ellis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470854     DOI: 10.1200/JCO.2006.09.8384

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.

Authors:  Jiaying Lyu; Yuan Ji; Naiqing Zhao; Daniel V T Catenacci
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-06-13       Impact factor: 1.864

2.  Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.

Authors:  David S Ziegler; Renee D Wright; Santosh Kesari; Madeleine E Lemieux; Mary A Tran; Monish Jain; Leigh Zawel; Andrew L Kung
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

3.  A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.

Authors:  Chunyan Cai; Ying Yuan; Yuan Ji
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2014-01-01       Impact factor: 1.864

4.  TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology.

Authors:  Wentian Guo; Yang Ni; Yuan Ji
Journal:  Stat Biosci       Date:  2015-06-30

5.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.